ANGPTL4 and cholangiocarcinoma: According to ROC curve analysis, ANGPTL4 could be applied as a biomarker to differentiate between HC and CCA patients with cutoff ≤ 0.2697 AU, sensitivity = 80.0% and specificity = 72.7% (AUC = 0.825, 95% CI 0.751–0.899, YI = 0.527, p < 0.0001) (Figure 3B).